Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AQP1 | P29972 | 3/20 | 0.58 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.37 |
| ▸ | LPAR5 | Q9H1C0 | 3/20 | 0.37 |
| ▸ | OXTR | P30559 | 2/20 | 0.37 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 2/20 | 0.34 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4231505 | 0.91 | AQP1 (0.47) | AQP1LPAR1LPAR5OXTRAVPR1A | |
| SCHEMBL4229920 | 0.91 | AQP1 (0.45) | AQP1LPAR1LPAR5OXTRAVPR1A | |
| SCHEMBL4596351 | 0.88 | AQP1 (0.45) | AQP1OXTRAVPR1AMEN1KMT2A | |
| SCHEMBL6368626 | 0.87 | AQP1 (0.40) | AQP1LPAR1LPAR5OXTRAVPR1A | |
| SCHEMBL4229679 | 0.84 | OXTR (0.42) | AQP1LPAR1LPAR5OXTRAVPR1A | |
| SCHEMBL6047928 | 0.83 | OXTR (0.37) | AQP1OXTRAVPR1ATDP1 | |
| SCHEMBL6367712 | 0.82 | TDP1 (0.41) | AQP1LPAR1LPAR5OXTRAVPR1A | |
| SCHEMBL4219301 | 0.82 | OXTR (0.43) | AQP1LPAR1LPAR5OXTRAVPR1A | |
| SCHEMBL4229060 | 0.81 | OXTR (0.39) | LPAR1LPAR5OXTRAVPR1AMEN1 | |
| SCHEMBL6368474 | 0.81 | HTR2A (0.38) | AQP1LPAR1LPAR5OXTRAVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1874750-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | Wyeth Incoporated (US) | 2008-01-09 | — | — | EP | disclosed |
| US-20050261347-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | WYETH (US) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261347-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | ADRA2A, HTR2A, ADRA1A | AQP1 2290/4885LPAR1 460/4885LPAR5 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.